Table 3.

Phenotype of CYC Responsive and Non-Responsive subgroups.

CHARACTERISTICS	Unselected Patients	Predicted as CYC Responsive (MaxFIB ≥3 and/or mRSS ≥23)	Predicted as CYC Non-Responsive (MaxFIB <3 and mRSS <23)	p-value†
Demographic
Number	112	53	57
Age, yrs	46.9 (0.9)*	47.5 (1.5)	46.2 (1.5)	0.56
Male, %	29.5	34.0	26.3	0.38
Duration of SSc, yrs	3.2 (0.2)	3.12 (0.3)	3.3 (0.3)	0.51
Smoking history, %	34%	29%	39%	0.25
Pulmonary Function
FVC, %-predicted	68.8 (0.9)	65.8 (1.6)	71.6 (1.5)	(<0.01)
TLC, %-predicted	69.8 (1.1)	67.2 (1.8)	73.5 (1.8)	(0.02)
DLCO, %-predicted	47.6 (1.0)	42.6 (1.6)	52.3 (1.5)	(<0.01)
BAL Cell Counts
% PMN	5.90 (0.51)	7.06 (0.85)	5.08 (0.86)	0.13
% EOS	2.89 (0.34)	3.90 (0.75)	2.10 (0.34)	(0.03)
HRCT Scores
MaxGGO, 0-4 scale	0.69 (0.06)	0.65 (0.09)	0.72 (0.11)	0.62
MaxFIB, 0-4 scale	1.95 (0.08)	2.65 (0.13)	1.33 (0.09)	NA
MaxHC, 0-4 scale	0.37 (0.04)	0.51 (0.07)	0.25 (0.07)	(0.01)
Skin Involvement
mRSS, 0-51 scale	14.9 (0.8)	19.2 (1.7)	10.9 (0.9)	NA
dcSSc, %	61.6	64.2	57.9	0.50
Symptoms
BDI, 0-12 scale	5.4 (0.2)	5.6 (0.3)	5.2 (0.2)	0.29
HAQ-DI, 0-3 scale	0.81 (0.06)	0.97 (0.11)	0.62 (0.07)	(<0.01)

^*(SEM)

^†Comparison of the “Predicted as CYC Responsive” and “Predicted as CYC Non-Responsive” subsets by t-test or chi-square. p≤0.05 noted with parentheses.